• Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia

    11 days ago - By San Diego Biotechnology

    ION449 met primary endpoint in Phase 2b SOLANO study for patients with hypercholesterolemia ION449 will not advance into Phase 3 development based on pre-specified criteria CARLSBAD, Calif., Sept. 23, 2022 /PRNewswire/ - Ionis Pharmaceuticals,...
    Read more ...